Mark Schena - Arrayit President
| ARYC Stock | USD 0.0001 0.00 0.00% |
President
Dr. Mark Schena, Ph.D., is President, Chief Technology Officer, Treasurer, Secretary, Director of Arrayit Corporationration Dr. Schena graduated first in his class with a PhD in Biochemistry in 1990 from the University of California at San Francisco. In 1995, as a postdoctoral fellow at Stanford University, he published the first paper on microarrays in the premier scientific journal Science, introducing microarrays to the world as a new scientific technology. His work rapidly led to a new field of discovery that uses microarrays to investigate both genes and proteins in research and diagnostics. Today, microarrays are used in more than 100, 000 laboratories in 50 countries to help address complicated questions in biology, chemistry, agriculture and medicine. The microarray field to date has produced 550, 000 scientific publications. Moreover, the commercial expansion of microarray technologies has created a multibillion dollar industry with over 200 companies producing ancillary products and services. Acknowledged by his peers for the importance of these accomplishments, in 2003 Dr. Schena was proclaimed the Father of Microarray Technology by The Scientist, a broadly read scientific journal. In 2009, Dr. Schena was proclaimed the Father of Microarrays by Drug Discovery News, further reinforcing his leadership position in the field. Dr. Schena has authored five foundational books on the subject of microarrays, including the bestselling text, Microarray Analysis and has published more than 30 important papers in scientific journals. since 2014.
| Age | 61 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 927 Thompson Place, Sunnyvale, CA, United States, 94085 |
| Phone | 408-744-1331 |
| Web | https://www.arrayit.com |
Arrayit Management Efficiency
The company has return on total asset (ROA) of (2.104) % which means that it has lost $2.104 on every $100 spent on assets. This is way below average. Arrayit's management efficiency ratios could be used to measure how well Arrayit manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -3.13. In addition to that, Return On Capital Employed is expected to decline to 0.61. At present, Arrayit's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 38.90, whereas Total Assets are forecasted to decline to about 989.9 K.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Esteban Santos | Amgen Inc | 56 | |
| Jonathan Graham | Amgen Inc | 63 | |
| Robert Krcmarov | Barrick Gold Corp | 55 | |
| Darian Rich | Barrick Gold Corp | 63 | |
| Luis Rojo | Stepan Company | 51 | |
| Scott Behrens | Stepan Company | 54 | |
| Daniel Barber | Aquestive Therapeutics | 48 | |
| Deni Nicoski | Barrick Gold Corp | N/A | |
| Murdo Gordon | Amgen Inc | 57 | |
| Debra Stefaniak | Stepan Company | 59 | |
| Reuven Spiegel | Delek Logistics Partners | 68 | |
| Sean Moriarty | Stepan Company | 51 | |
| Kevin Kremke | Delek Logistics Partners | 46 | |
| Odely Sakazi | Delek Logistics Partners | 40 | |
| Avigal Soreq | Delek Logistics Partners | 46 | |
| Greg Walker | Barrick Gold Corp | 59 | |
| Daniel Gordon | Delek Logistics Partners | 40 | |
| Kevin Thomson | Barrick Gold Corp | 67 | |
| Peter Boyd | Aquestive Therapeutics | 58 | |
| Matthew Eaken | Stepan Company | 61 | |
| Frederec Green | Delek Logistics Partners | 55 | |
Management Performance
| Return On Asset | -2.1 |
Arrayit Leadership Team
Elected by the shareholders, the Arrayit's board of directors comprises two types of representatives: Arrayit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrayit. The board's role is to monitor Arrayit's management team and ensure that shareholders' interests are well served. Arrayit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrayit's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rene Schena, Chairman, CEO and CFO | ||
| Mark Schena, President, Chief Science Officer, Treasurer, Secretary, Scientific Advisor and Director | ||
| Paul Haje, Vice Marketing | ||
| Ronald Cole, Consultant | ||
| Todd Martinsky, Founder, Executive VP, Scientific Advisor and Director | ||
| William Sklar, Financial Consultant |
Arrayit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrayit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -2.1 | ||||
| Profit Margin | (2.31) % | ||||
| Operating Margin | (5.20) % | ||||
| Current Valuation | 112.65 K | ||||
| Shares Outstanding | 1.13 B | ||||
| Shares Owned By Insiders | 14.80 % | ||||
| Price To Earning | (0.20) X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 4.38 M | ||||
| Gross Profit | 2.58 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Arrayit offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arrayit's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arrayit Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arrayit Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrayit. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Arrayit Stock refer to our How to Trade Arrayit Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrayit. If investors know Arrayit will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrayit listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.015 | Quarterly Revenue Growth 0.249 | Return On Assets (2.10) |
The market value of Arrayit is measured differently than its book value, which is the value of Arrayit that is recorded on the company's balance sheet. Investors also form their own opinion of Arrayit's value that differs from its market value or its book value, called intrinsic value, which is Arrayit's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrayit's market value can be influenced by many factors that don't directly affect Arrayit's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrayit's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrayit is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrayit's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.